Proguardeum

Proguardeum is a biotechnology company dedicated to developing novel therapies for chronic fibrotic and inflammatory diseases. The company's lead program is a monoclonal antibody targeting P-selectin, a cell adhesion molecule that plays a critical role in the recruitment of inflammatory cells to sites of tissue injury. By inhibiting P-selectin, Proguardeum aims to disrupt the cycle of inflammation and fibrosis in organs such as the liver, lungs, and kidneys. The company was founded based on research from the University of California, San Diego, and is led by experts in vascular biology and drug development. Their primary focus areas include nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).